NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 927.3 DKK | +1.13% |
|
-0.16% | +32.83% |
| 31/05 | Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment | MT |
| 30/05 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
| Sales 2024 * | 290B 42.24B 3,523B | Sales 2025 * | 350B 50.95B 4,250B | Capitalization | 4,113B 598B 49,901B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.19B 1,267B | Net income 2025 * | 127B 18.49B 1,542B | EV / Sales 2024 * | 14.2 x |
| Net Debt 2024 * | 13.47B 1.96B 163B | Net cash position 2025 * | 13.31B 1.94B 161B | EV / Sales 2025 * | 11.7 x |
| P/E ratio 2024 * |
39.8
x | P/E ratio 2025 * |
32.6
x | Employees | 66,015 |
| Yield 2024 * |
1.29% | Yield 2025 * |
1.56% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +1.13% | ||
| 1 week | -0.16% | ||
| 1 month | +2.74% | ||
| 3 months | +13.13% | ||
| 6 months | +33.33% | ||
| Current year | +32.83% |
1 week
906.40
931.60
1 month
826.70942.60
Current year
688.80942.60
1 year
504.40942.60
3 years
239.80942.60
5 years
155.30942.60
10 years
109.10942.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/91/01 | |
| Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +16.70% | ||
| 10.45% | 5 M€ | +15.85% | ||
| 5.40% | 17 M€ | +6.09% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 927.3 | +1.13% | 5,539,486 |
| 30/24/30 | 916.9 | +0.59% | 2,132,021 |
| 29/24/29 | 911.5 | -0.46% | 2,491,686 |
| 28/24/28 | 915.7 | -0.43% | 2,086,119 |
| 27/24/27 | 919.7 | -0.98% | 1,129,526 |
Delayed Quote Nasdaq Copenhagen, May 31, 2024 at 08:29 pm IST
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| +40.73% | 739B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B | |
| -.--% | 122B |
- Stock Market
- Equities
- NOVO B Stock
